February 20, 2019 Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme
December 20, 2018 Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
November 28, 2018 Mustang Bio Announces Presentation of MB-102 (CD123 CAR) Safety and Efficacy Data at AACR Special Conference on Tumor Immunology and Immunotherapy
November 13, 2018 Mustang Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
October 30, 2018 Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope
October 1, 2018 Mustang Bio to Present at 8th Annual Partnering Forum at Cell & Gene Meeting on the Mesa
September 4, 2018 Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018
August 13, 2018 Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights